semaglutide inflammation arthritis Once-Weekly in Persons with Obesity and Knee Osteoarthritis Anti-inflammatory benefits of semaglutide: State

The FDA has documented adverse events related to compounded semaglutide, making it a less safe option compared to FDA-approved medications

A safer drug supply The FDA was pretty clear in their December 19, 2024 letter when they wrote: Although compounded drug products can provide treatment options for patients during a drug shortage, compounded drugs have not undergone FDA premarket review for safety, effectiveness, and quality, and lack a premarket inspection and finding of manufacturing quality that is part of the drug approval process

No clinical trials have evaluated split-dosing regimens

Lower doses may be appropriate, and additional monitoring may be necessary

Leaders are most successful when they enable others to succeed